New Orleans--Hurricane Katrina has come and gone and in its wake we are left with devastation, carnage, and sadness. The region has more than 6,000 displaced physicians, and 156 AUA members have practices in the affected areas, according to AUA.
New Orleans-Hurricane Katrina has come and gone and in its wake we are left with devastation, carnage, and sadness. The region has more than 6,000 displaced physicians, and 156 AUA members have practices in the affected areas, according to AUA.
The populace has not returned. The hospitals have reduced services because there are not enough orderlies, technicians, and housekeeping staff to support an entire facility. The schools were closed and therefore, there are no children, and thus there is no laughter anywhere. The stores do not have enough staff to open. For some strange reason, there are no birds singing. Nature has truly done a number on this wonderful city that is 8 feet below sea level.
Satish Karnick, MD, is a urologist practicing in New Orleans. He lost his practice, and the hospital where he worked has no immediate plans to reopen. His patient base in St. Bernard Parish was decimated by the storm. Like the rest of the nation, he watched his professional life unfold on CNN. A friend who had trained in New Orleans contacted Dr. Karnick and offered him a position at his clinic in Austin, TX.
"I've been feeling 'survivor guilt' about having a livable home and an out-of-town job that just landed on my lap a week after the hurricane," Dr. Karnick said. "I see my patients on TV and I feel that I have abandoned them. I wonder if I should be opening up an office in another part of town and bleeding my family's savings, or am I better off taking care of my own children's education through my income in Austin?"
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.